EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Points to Consider on the Use of Medicines in Pregnancy Throughout the Product Lifecycle Based on Global Regulatory Guidance

Amalia Alexe, Keele Wurst, Leesha Balramsingh-Harry, Olatayo Apara, Nadezda Abramova, Osa Eisele, Maria Fernanda Scantamburlo Fernandes, Anju Garg, Birgit Kovacs, David Lewis

Therapeutic Innovation & Regulatory Science · 2025

DOI: 10.1007/s43441-024-00736-0 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2025. Verfasst von Amalia Alexe und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Hertfordshire, Hertfordshire, UK. amalia.alexe@novartis.com. Hauptthemen laut MEDLINE: Pregnancy, Breast Feeding, Pharmacovigilance. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The thalidomide tragedy of the 1960s led to restrictions and limitations in the participation of pregnant women in clinical trials. Despite the paucity of information on the safe and effective use of medicines in this population, most pregnant women are prescribed medications. A landscape assessment review of guidelines and legislation governing the use of medicines in pregnancy and during breastfeeding was conducted by the TransCelerate Pharmacovigilance Pregnancy and Breastfeeding Team. Insights from the landscape assessment review were compiled to identify important points to consider concerning the use of medicines in pregnancy throughout a product lifecycle. Four main areas were identified for consideration for use of medicines in pregnancy: (1) Product development considerations: Key points on the disease itself, the medicine characteristics, non-clinical and clinical development. (2) Interventional study considerations: Key aspects in enrollment of pregnant women in clinical trials and the follow-up requirements for such women. (3) Post-marketing considerations: Key elements in spontaneous case reporting of medicines exposure during pregnancy, implementation of appropriate risk management plans for medicines likely to be used in pregnancy. (4) Full lifecycle considerations: Activities required by regulators to ensure safety surveillance and maintenance throughout product lifecycle. There is a need for harmonized guidance on how to study the use of medicine in pregnancy. This paper addresses regulatory considerations, to aid in the planning and execution of research programs focused on developing medicines for use in pregnancy when permissible under established regulatory framework.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PregnancyBreast FeedingPharmacovigilanceFemaleHumansClinical Trials as TopicProduct Surveillance, Postmarketing

Stichwörter der Autor:innen

BreastfeedingMaternal healthPatient safetyPharmacovigilance regulationsPregnancy

Autor:innen und Institutionen

  • University of Hertfordshire, Hertfordshire, UK. amalia.alexe@novartis.com.
  • , Rue de la Tour de L'Ile 4, Genève, 1204, Switzerland. amalia.alexe@novartis.com.
  • GlaxoSmithKline, London, UK.
  • Hoffman LaRoche Ltd., Basel, Switzerland.
  • Merck & Co., Inc., Rahway, USA.
  • Merck Healthcare KGaA, Darmstadt, Germany.

Zitieren

APA

Alexe, A., Wurst, K., Balramsingh-Harry, L., Apara, O., Abramova, N., Eisele, O., Fernandes, M. F. S., Garg, A., Kovacs, B., & Lewis, D. (2025). Points to Consider on the Use of Medicines in Pregnancy Throughout the Product Lifecycle Based on Global Regulatory Guidance. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-024-00736-0

Vancouver

Alexe A, Wurst K, Balramsingh-Harry L, Apara O, Abramova N, Eisele O, et al. Points to Consider on the Use of Medicines in Pregnancy Throughout the Product Lifecycle Based on Global Regulatory Guidance. Therapeutic Innovation & Regulatory Science. 2025. doi:10.1007/s43441-024-00736-0

BibTeX
@article{Alexe2025,
  author = {Alexe, Amalia and Wurst, Keele and Balramsingh-Harry, Leesha and Apara, Olatayo and Abramova, Nadezda and Eisele, Osa and Fernandes, Maria Fernanda Scantamburlo and Garg, Anju and Kovacs, Birgit and Lewis, David},
  title = {Points to Consider on the Use of Medicines in Pregnancy Throughout the Product Lifecycle Based on Global Regulatory Guidance},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2025},
  doi = {10.1007/s43441-024-00736-0}
}
Kostenlos starten →